Gufic Biosciences to grab major share of Rs3,000 crore Lyphilized antibiotics -; antifungal market in India

7 Jun 2022 , 10:25 AM

Gufic Biosciences Limited has targeted to capture a major share of the Rs3,000 crore lyophilized antibacterial market in India.

Gufic has launched New Drug Delivery System called Dual Chamber Bags at an affordable price for the first time in India.

Gufic has collaborated with its European counterpart to manufacture this new technology indigenously in India as part of its ambitious Make in India drive. Until now the dual-chamber bags were imported to India at a very high cost to the patients.

On the contrary, Gufic has not only launched high-quality Dual Chamber Bags at an affordable and pocket-friendly price, these New Drug Delivery System products even have a longer shelf -life, stated media reports.

Dr. Debesh Das, COO-Domestic Formulation said, ‘We are focused to reduce the country’s dependency on imported products, especially in the critical care segment. Advancing with this vision, we have introduced indigenously produced Dual Chamber Bags of global standards in India at affordable prices. As we are experiencing rapidly growing demand for our products, we look forward to grabbing major market share in this particular segment.”

At around 10.28 AM, Gufic BioSciences was trading at Rs231.20 up by Rs8.55 or 3.84% from its previous closing of Rs222.65 on the BSE. The scrip opened at Rs228.90 and has touched intraday high and low of Rs234 and Rs226 respectively.